NASDAQ:XENT

Intersect ENT Competitors

$20.49
+0.34 (+1.69 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.02
Now: $20.49
$20.70
50-Day Range
$19.14
MA: $21.83
$24.37
52-Week Range
$8.70
Now: $20.49
$26.98
Volume122,055 shs
Average Volume209,513 shs
Market Capitalization$676.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34

Competitors

Intersect ENT (NASDAQ:XENT) Vs. AXNX, INO, GNMK, SILK, ATEC, and LMNX

Should you be buying XENT stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Intersect ENT, including Axonics Modulation Technologies (AXNX), Inovio Pharmaceuticals (INO), GenMark Diagnostics (GNMK), Silk Road Medical (SILK), Alphatec (ATEC), and Luminex (LMNX).

Axonics Modulation Technologies (NASDAQ:AXNX) and Intersect ENT (NASDAQ:XENT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares Axonics Modulation Technologies and Intersect ENT's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axonics Modulation Technologies-76.62%-28.05%-23.44%
Intersect ENT-71.96%-55.81%-40.23%

Analyst Ratings

This is a summary of current ratings and recommmendations for Axonics Modulation Technologies and Intersect ENT, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axonics Modulation Technologies00703.00
Intersect ENT14302.25

Axonics Modulation Technologies presently has a consensus target price of $64.25, suggesting a potential upside of 6.85%. Intersect ENT has a consensus target price of $23.4286, suggesting a potential upside of 14.34%. Given Intersect ENT's higher probable upside, analysts plainly believe Intersect ENT is more favorable than Axonics Modulation Technologies.

Risk & Volatility

Axonics Modulation Technologies has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Valuation and Earnings

This table compares Axonics Modulation Technologies and Intersect ENT's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axonics Modulation Technologies$13.82 million180.66$-79,930,000.00($2.80)-21.48
Intersect ENT$109.14 million6.20$-42,990,000.00($1.37)-14.96

Intersect ENT has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

84.2% of Axonics Modulation Technologies shares are held by institutional investors. Comparatively, 84.3% of Intersect ENT shares are held by institutional investors. 25.7% of Axonics Modulation Technologies shares are held by insiders. Comparatively, 3.5% of Intersect ENT shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Intersect ENT beats Axonics Modulation Technologies on 8 of the 14 factors compared between the two stocks.

Intersect ENT (NASDAQ:XENT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Intersect ENT and Inovio Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intersect ENT14302.25
Inovio Pharmaceuticals14302.25

Intersect ENT presently has a consensus price target of $23.4286, suggesting a potential upside of 14.34%. Inovio Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 94.95%. Given Inovio Pharmaceuticals' higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Intersect ENT.

Valuation & Earnings

This table compares Intersect ENT and Inovio Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intersect ENT$109.14 million6.20$-42,990,000.00($1.37)-14.96
Inovio Pharmaceuticals$4.11 million441.95$-119,360,000.00($1.16)-7.52

Intersect ENT has higher revenue and earnings than Inovio Pharmaceuticals. Intersect ENT is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intersect ENT and Inovio Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intersect ENT-71.96%-55.81%-40.23%
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%

Institutional & Insider Ownership

84.3% of Intersect ENT shares are owned by institutional investors. Comparatively, 36.0% of Inovio Pharmaceuticals shares are owned by institutional investors. 3.5% of Intersect ENT shares are owned by insiders. Comparatively, 4.0% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Intersect ENT has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Summary

Intersect ENT beats Inovio Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Profitability

This table compares GenMark Diagnostics and Intersect ENT's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
Intersect ENT-71.96%-55.81%-40.23%

Institutional and Insider Ownership

96.9% of GenMark Diagnostics shares are owned by institutional investors. Comparatively, 84.3% of Intersect ENT shares are owned by institutional investors. 3.3% of GenMark Diagnostics shares are owned by insiders. Comparatively, 3.5% of Intersect ENT shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares GenMark Diagnostics and Intersect ENT's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.92$-47,350,000.00($0.82)-29.26
Intersect ENT$109.14 million6.20$-42,990,000.00($1.37)-14.96

Intersect ENT has higher revenue and earnings than GenMark Diagnostics. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

GenMark Diagnostics has a beta of 3.02, meaning that its share price is 202% more volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for GenMark Diagnostics and Intersect ENT, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
Intersect ENT14302.25

GenMark Diagnostics presently has a consensus price target of $22.0125, suggesting a potential downside of 8.24%. Intersect ENT has a consensus price target of $23.4286, suggesting a potential upside of 14.34%. Given Intersect ENT's stronger consensus rating and higher probable upside, analysts plainly believe Intersect ENT is more favorable than GenMark Diagnostics.

Silk Road Medical (NASDAQ:SILK) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Insider & Institutional Ownership

84.3% of Intersect ENT shares are owned by institutional investors. 7.8% of Silk Road Medical shares are owned by company insiders. Comparatively, 3.5% of Intersect ENT shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Silk Road Medical and Intersect ENT's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silk Road Medical-53.66%-40.79%-24.56%
Intersect ENT-71.96%-55.81%-40.23%

Analyst Recommendations

This is a summary of recent ratings and target prices for Silk Road Medical and Intersect ENT, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silk Road Medical02202.50
Intersect ENT14302.25

Silk Road Medical presently has a consensus target price of $61.75, suggesting a potential upside of 23.16%. Intersect ENT has a consensus target price of $23.4286, suggesting a potential upside of 14.34%. Given Silk Road Medical's stronger consensus rating and higher probable upside, analysts plainly believe Silk Road Medical is more favorable than Intersect ENT.

Risk and Volatility

Silk Road Medical has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Valuation & Earnings

This table compares Silk Road Medical and Intersect ENT's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silk Road Medical$63.35 million27.20$-52,420,000.00($1.36)-36.87
Intersect ENT$109.14 million6.20$-42,990,000.00($1.37)-14.96

Intersect ENT has higher revenue and earnings than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Summary

Silk Road Medical beats Intersect ENT on 9 of the 14 factors compared between the two stocks.

Intersect ENT (NASDAQ:XENT) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Profitability

This table compares Intersect ENT and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intersect ENT-71.96%-55.81%-40.23%
Alphatec-51.95%-266.45%-40.80%

Earnings & Valuation

This table compares Intersect ENT and Alphatec's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intersect ENT$109.14 million6.20$-42,990,000.00($1.37)-14.96
Alphatec$113.43 million14.76$-57,000,000.00($1.09)-16.15

Intersect ENT has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Intersect ENT and Alphatec, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intersect ENT14302.25
Alphatec00703.00

Intersect ENT currently has a consensus price target of $23.4286, suggesting a potential upside of 14.34%. Alphatec has a consensus price target of $15.4286, suggesting a potential downside of 12.34%. Given Intersect ENT's higher probable upside, analysts plainly believe Intersect ENT is more favorable than Alphatec.

Insider & Institutional Ownership

84.3% of Intersect ENT shares are held by institutional investors. Comparatively, 31.8% of Alphatec shares are held by institutional investors. 3.5% of Intersect ENT shares are held by company insiders. Comparatively, 28.2% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Intersect ENT has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.

Summary

Alphatec beats Intersect ENT on 8 of the 14 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Luminex and Intersect ENT's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luminex4.60%3.75%2.73%
Intersect ENT-71.96%-55.81%-40.23%

Earnings and Valuation

This table compares Luminex and Intersect ENT's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luminex$334.64 million4.66$-3,840,000.00($0.21)-156.90
Intersect ENT$109.14 million6.20$-42,990,000.00($1.37)-14.96

Luminex has higher revenue and earnings than Intersect ENT. Luminex is trading at a lower price-to-earnings ratio than Intersect ENT, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Luminex and Intersect ENT, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luminex00103.00
Intersect ENT14302.25

Luminex presently has a consensus price target of $38.00, suggesting a potential upside of 15.33%. Intersect ENT has a consensus price target of $23.4286, suggesting a potential upside of 14.34%. Given Luminex's stronger consensus rating and higher probable upside, equities research analysts plainly believe Luminex is more favorable than Intersect ENT.

Risk and Volatility

Luminex has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Insider & Institutional Ownership

88.1% of Luminex shares are held by institutional investors. Comparatively, 84.3% of Intersect ENT shares are held by institutional investors. 9.4% of Luminex shares are held by insiders. Comparatively, 3.5% of Intersect ENT shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Luminex beats Intersect ENT on 11 of the 14 factors compared between the two stocks.


Intersect ENT Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$60.13+0.2%$2.50 billion$13.82 million-30.68
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72+0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14+0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60+1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95+2.0%$1.56 billion$334.64 million84.49News Coverage
Gap Up
Pulmonx logo
LUNG
Pulmonx
1.4$43.48+4.7%$1.55 billion$32.60 million0.00Insider Selling
Gap Down
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13+0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72+5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76+0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00+0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44+2.0%$1.06 billion$117.23 million55.31Gap Up
Cerus logo
CERS
Cerus
1.7$6.13+1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55+0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77+1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61+0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87+1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14+0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
SeaSpine logo
SPNE
SeaSpine
1.3$21.94+2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26+0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81+1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00+1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21+0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55+1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12+1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07+0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50+3.9%$415.95 million$4.17 million-17.52News Coverage
Gap Up
Soliton logo
SOLY
Soliton
1.1$18.25+0.1%$386.90 millionN/A-24.33
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.90+0.2%$385.05 million$24.95 million-26.97
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.73+0.7%$373.97 million$198.38 million24.87
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.20+0.5%$370.85 million$2.84 million0.00
Apyx Medical logo
APYX
Apyx Medical
1.0$9.50+3.7%$326.02 million$28.15 million-20.21Analyst Downgrade
Gap Up
Neuronetics logo
STIM
Neuronetics
1.5$12.79+2.5%$324.97 million$62.66 million-7.61Gap Up
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54+1.0%$319.17 million$46.90 million27.62News Coverage
DarioHealth logo
DRIO
DarioHealth
1.1$20.62+3.9%$317.45 million$7.56 million-2.58Gap Up
IRadimed logo
IRMD
IRadimed
1.5$24.04+3.0%$295.96 million$38.52 million75.13News Coverage
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.10+2.2%$260.86 million$220,000.0011.23
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.53+0.7%$227.19 million$8.34 million-2.22
Titan Medical logo
TMDI
Titan Medical
1.2$1.82+7.1%$199.34 millionN/A182.00Analyst Report
Analyst Revision
News Coverage
Gap Down
TELA Bio logo
TELA
TELA Bio
2.1$13.72+0.0%$198.12 million$15.45 million-4.71
NMRD
Nemaura Medical
0.2$6.96+3.6%$159.59 millionN/A-34.80Gap Up
PolyPid logo
PYPD
PolyPid
1.4$9.33+2.0%$159.04 millionN/A0.00Gap Up
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.44+0.6%$153.00 million$23.16 million-344.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.66+1.1%$147.07 million$50.71 million-4.56Gap Up
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.20+1.0%$145.02 millionN/A0.00
Avinger logo
AVGR
Avinger
1.3$1.50+0.7%$142.95 million$9.13 million-1.15News Coverage
Gap Up
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.